BRPI0922619A2 - compostos de plasmalogen, composições farmacêuticas contendo os mesmos e métodos para tratar doenças do envelhecimento - Google Patents

compostos de plasmalogen, composições farmacêuticas contendo os mesmos e métodos para tratar doenças do envelhecimento

Info

Publication number
BRPI0922619A2
BRPI0922619A2 BRPI0922619A BRPI0922619A BRPI0922619A2 BR PI0922619 A2 BRPI0922619 A2 BR PI0922619A2 BR PI0922619 A BRPI0922619 A BR PI0922619A BR PI0922619 A BRPI0922619 A BR PI0922619A BR PI0922619 A2 BRPI0922619 A2 BR PI0922619A2
Authority
BR
Brazil
Prior art keywords
plasmalogen
compounds
methods
pharmaceutical compositions
compositions containing
Prior art date
Application number
BRPI0922619A
Other languages
English (en)
Inventor
Dayan Goodenowe
M Amin Khan
Paul L Wood
Pearson Ahiahonu
Rishikesh Mankidy
Original Assignee
Phenomenome Discoveries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phenomenome Discoveries Inc filed Critical Phenomenome Discoveries Inc
Publication of BRPI0922619A2 publication Critical patent/BRPI0922619A2/pt
Publication of BRPI0922619A8 publication Critical patent/BRPI0922619A8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C07C323/59Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/22Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D339/00Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02Five-membered rings
    • C07D339/04Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • C07F9/10Phosphatides, e.g. lecithin
    • C07F9/106Adducts, complexes, salts of phosphatides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0922619A 2008-12-22 2009-12-18 Compostos de plasmalogen, composições farmacêuticas contendo os mesmos e métodos para tratar doenças do envelhecimento BRPI0922619A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13969508P 2008-12-22 2008-12-22
PCT/CA2009/001853 WO2010071988A1 (en) 2008-12-22 2009-12-18 Plasmalogen compounds, pharmaceutical compositions containing the same and methods for treating diseases of the aging

Publications (2)

Publication Number Publication Date
BRPI0922619A2 true BRPI0922619A2 (pt) 2016-09-13
BRPI0922619A8 BRPI0922619A8 (pt) 2023-01-10

Family

ID=42286823

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0922619A BRPI0922619A8 (pt) 2008-12-22 2009-12-18 Compostos de plasmalogen, composições farmacêuticas contendo os mesmos e métodos para tratar doenças do envelhecimento

Country Status (17)

Country Link
US (1) US9334235B2 (pt)
EP (1) EP2382201B1 (pt)
JP (2) JP5740312B2 (pt)
KR (1) KR101810988B1 (pt)
CN (2) CN102369193B (pt)
AR (2) AR074854A1 (pt)
AU (1) AU2009329784B2 (pt)
BR (1) BRPI0922619A8 (pt)
CA (1) CA2746831C (pt)
IL (1) IL213409A0 (pt)
MX (1) MX350291B (pt)
MY (1) MY169797A (pt)
RU (1) RU2546108C2 (pt)
SG (1) SG172340A1 (pt)
TW (1) TWI475989B (pt)
UY (1) UY32359A (pt)
WO (1) WO2010071988A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010100060A2 (en) * 2009-03-04 2010-09-10 Nestec S.A. Method for increasing endogenous plasmalogen levels in mammals
SG10201405975VA (en) 2009-10-01 2014-11-27 Phenomenome Discoveries Inc Serum-based biomarkers of pancreatic cancer and uses thereof for diseasedetection and diagnosis
JP5997887B2 (ja) * 2011-09-05 2016-09-28 学校法人帝京大学 経口投与剤
JP5934483B2 (ja) * 2011-09-05 2016-06-15 学校法人帝京大学 リン脂質結合型dha増加剤
WO2015064960A1 (ko) 2013-10-29 2015-05-07 울산대학교 산학협력단 플라스마로젠 전구체, 플라스마로젠 또는 플라스마로젠 유사체를 유효성분으로 함유하는 간질환 예방 또는 치료용 약학조성물
WO2016041013A1 (en) * 2014-09-16 2016-03-24 Baker Idi Heart And Diabetes Institute Holdings Limited Glycerolipids and uses therefor
CN108276438B (zh) * 2018-02-02 2020-05-22 中国海洋大学 一种epa缩醛磷脂的制备方法及其应用
CN112166116B (zh) 2018-04-27 2024-04-12 株式会社流变机能食品研究所 新型缩醛磷脂衍生物
WO2020009173A1 (ja) * 2018-07-06 2020-01-09 丸大食品株式会社 プラズマローゲン含有組成物
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
CN112321446A (zh) * 2020-11-25 2021-02-05 华南理工大学 一种酰胺衍生物的合成方法
CN113150270A (zh) * 2021-03-19 2021-07-23 广东丁沃生医疗器械有限公司 一种磷脂聚合物及其制备方法与应用
JP7704407B2 (ja) * 2021-08-04 2025-07-08 株式会社 レオロジー機能食品研究所 がん治療用組成物
JP7629164B2 (ja) * 2021-08-23 2025-02-13 株式会社 レオロジー機能食品研究所 新規プラズマローゲン誘導体
KR20240113765A (ko) 2021-11-22 2024-07-23 가부시키가이샤 레오로지 키노쇼쿠힝겐큐죠 화합물, 이의 라세미체, 이들의 염, 조성물, 항염증제, 인지증 치료제 및 레트 증후군 치료제
WO2024111529A1 (ja) * 2022-11-21 2024-05-30 株式会社 レオロジー機能食品研究所 脳プラズマローゲン増加剤、脳プラズマローゲン増加用経口組成物及び化合物の使用
WO2025057845A1 (ja) * 2023-09-11 2025-03-20 株式会社 レオロジー機能食品研究所 抗老化剤、抗老化用経口組成物及び化合物の使用
CN119876292B (zh) * 2025-03-27 2025-06-03 浙江省白马湖实验室有限公司 一种酰胺类缩醛磷脂化合物的制备方法及应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4827011A (en) * 1984-12-10 1989-05-02 American Cyanamid Company Antihypertensive phosphate derivatives
FR2736265B1 (fr) 1995-07-07 1997-09-26 Forgeot Marcel Nouvelles compositions a base de phosphoglycero ethers et leur utilisation dans le traitement des maladies neuro-degeneratives
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
US6838452B2 (en) 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
JP2004026803A (ja) 2002-03-29 2004-01-29 Nof Corp 神経細胞死予防剤
US20080020472A1 (en) 2005-11-22 2008-01-24 Frantz Biomarkers, Llc Method for detecting an inflammatory disease or cancer
KR20080104350A (ko) 2006-02-28 2008-12-02 페노미넘 디스커버리스 인코포레이티드 치매 및 다른 신경 장애의 진단을 위한 방법
US20080021000A1 (en) 2006-07-19 2008-01-24 Su Chen Mixtures of and methods of use for polyunsaturated fatty acid-containing phospholipids and alkyl ether phospholipids species
JP2008125365A (ja) * 2006-11-16 2008-06-05 Kagoshima Univ 高純度プラスマローゲン調製法
JPWO2008093709A1 (ja) * 2007-01-30 2010-05-20 株式会社プロジェクト・エム アミロイド蛋白質の凝集抑制および分解促進によりアミロイドーシスと関連する疾患を予防または治療するための組成物
EP2620147B1 (en) 2007-02-08 2020-06-03 Med-Life Discoveries LP Compounds for lowering cholesterol
JP5220842B2 (ja) 2007-04-13 2013-06-26 フェノメノーム ディスカバリーズ インク プラスマロゲン欠乏症が媒介する加齢に伴う疾患の診断及びリスク評価のための方法

Also Published As

Publication number Publication date
MX350291B (es) 2017-09-04
US9334235B2 (en) 2016-05-10
TW201034662A (en) 2010-10-01
CN105859680A (zh) 2016-08-17
UY32359A (es) 2010-05-31
IL213409A0 (en) 2011-07-31
JP2012512816A (ja) 2012-06-07
AU2009329784B2 (en) 2016-08-25
CA2746831A1 (en) 2010-07-01
AR074854A1 (es) 2011-02-16
US20120035250A1 (en) 2012-02-09
MY169797A (en) 2019-05-15
CN102369193A (zh) 2012-03-07
WO2010071988A1 (en) 2010-07-01
MX2011006795A (es) 2011-09-26
EP2382201B1 (en) 2022-08-24
EP2382201A4 (en) 2015-11-18
US20130116312A2 (en) 2013-05-09
SG172340A1 (en) 2011-07-28
WO2010071988A8 (en) 2011-07-21
KR20110104002A (ko) 2011-09-21
CN102369193B (zh) 2016-05-04
TWI475989B (zh) 2015-03-11
JP2015145388A (ja) 2015-08-13
RU2546108C2 (ru) 2015-04-10
CA2746831C (en) 2013-11-26
BRPI0922619A8 (pt) 2023-01-10
KR101810988B1 (ko) 2017-12-20
JP5740312B2 (ja) 2015-06-24
RU2011124579A (ru) 2013-01-27
EP2382201A1 (en) 2011-11-02
AR117572A2 (es) 2021-08-18
AU2009329784A1 (en) 2011-07-07

Similar Documents

Publication Publication Date Title
BRPI0922619A2 (pt) compostos de plasmalogen, composições farmacêuticas contendo os mesmos e métodos para tratar doenças do envelhecimento
BR112014011671A2 (pt) composto, composição farmacêutica, método para o tratamento de uma doença ou condição, e, uso de um composto
BRPI0819218A2 (pt) Métodos, estojos e composições para administração de compostos farmacêuticos
BR112014003681A2 (pt) composto, composição farmacêutica, produto de combinação farmacêutica, uso de um composto, e, método para tratar doenças ou condições
BRPI0810082A2 (pt) 3-imidazolil-indóis para o tratamento de doenças proliferativas
BR112013026341A2 (pt) composto, composição farmacêutica, e, método para tratar, prevenir e/ou atrasar o início de uma doença ou patologia
BR112014029674A2 (pt) composto, composição farmacêutica, método para o tratamento de uma doença, utilização de um composto, conjunto para o tratamento de uma condição mediada pela quinase pim e invenção
BR112012026570A2 (pt) composto, composição farmacêutica, uso de um composto, método para o tratamento de um indíviduo e produto combinado
BR112014008126A2 (pt) composto, método para o tratamento, composição farmacêutica, utilização de um composto e invenção
PT2367561E (pt) Composições e métodos para o tratamento da doença celíaca
BRPI0813725A2 (pt) Métodos e composições para tratamento de doenças
BRPI0916684A2 (pt) Compostos de piperazina, composição, e, processo para combater vegetação indesejada
BRPI1005153A2 (pt) composto, composição farmacêutica, uso de um composto, metodo para tratar um indivíduo que sofre de uma condição patológica ou doença e produto de combinação
BRPI0908026A2 (pt) Métodos para o tratamento de doenças do intestino
BRPI0911685A2 (pt) composto, método para o tratamento de uma doença, uso de um composto, composição farmacêutica, e, kit
BRPI0919238A2 (pt) métodos e composições para o tratamento de câncer
PT2632452T (pt) Compostos e composições para o tratamento do cancro
BRPI0909164A2 (pt) método e composições para o tratamento de câncer
BR112015006512A2 (pt) composição para tratar tecidos biológicos danificados
BR112014009889A2 (pt) compostos dissubstituídos, compostos e composição farmacêutica
BRPI0908334A2 (pt) kit, composição, produto ou medicamento para tratar comprometimento cognitivo
BRPI0911580A2 (pt) composições para o tratamento de uma condição artrítica
BR112014001015A2 (pt) agente de cura para composições de cura por umidade
BRPI0923909A2 (pt) Método para tratar uma ou mais hastes de cabelo
BRPI0917562A2 (pt) composições farmacêuticas e métodos para estabilizar as mesmas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B25D Requested change of name of applicant approved

Owner name: MED-LIFE DISCOVERIES LP (CA)

B25G Requested change of headquarter approved

Owner name: MED-LIFE DISCOVERIES LP (CA)